Clinical Trial Update: Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating the efficacy and safety of Oxabact in reducing urinary oxalate in patients with primary hyperoxaluria has completed Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria

Drugs mentioned

• Oxabact

Snippet

Sponsor: OxThera | Conditions: Primary Hyperoxaluria | Phase 2, Phase 3 | Status: COMPLETED